Patents by Inventor Marcus E. Peter
Marcus E. Peter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959082Abstract: Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.” The disclosed toxic RNAi active seed sequences may be referred to as “dual activity super toxic RNAi active dsRNAs” that include a toxic first strand and a toxic second strand that is complementary to the toxic first strand. As such, the disclosed dsRNAs may be expressed as shRNAs which are processed for RNA interference (RNAi) and either of the toxic first strand and the toxic second strand can function as a guide strand to initiate RNAi.Type: GrantFiled: March 19, 2020Date of Patent: April 16, 2024Assignee: Northwestern UniversityInventors: Marcus E. Peter, Andrea E. Murmann
-
Publication number: 20240076677Abstract: Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). The disclosed polynucleotides, compositions, and methods may be utilized for treating diseases and disorders through RNAi. Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.Type: ApplicationFiled: March 1, 2023Publication date: March 7, 2024Inventors: Marcus E. Peter, William E. Putzbach, Andrea E. Murmann, Monal Patel, Quan Gao
-
Patent number: 11613754Abstract: Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). The disclosed polynucleotides, compositions, and methods may be utilized for treating diseases and disorders through RNAi. Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.Type: GrantFiled: February 20, 2018Date of Patent: March 28, 2023Assignee: Northwestern UniversityInventors: Marcus E. Peter, William E. Putzbach, Andrea E. Murmann, Monal Patel, Quan Gao
-
Patent number: 11312958Abstract: Disclosed are components and methods for producing toxic RNAs and/or extracellular vesicles comprising the toxic RNAs in cells that are resistant to the toxic RNAs, which toxic RNAs may include toxic shRNA/siRNA and/or toxic pre-miRNA/miRNA. The disclosed components may include engineered cells that can be utilized to express the toxic RNAs, in which the engineered cells do not express one or more genes that are required for processing the toxic RNAs for RNA interference (RNAi) and/or one or more genes that are required for executing RNAi. The toxic RNAs and/or extracellular vesicles comprising the toxic RNAs may be utilized in methods for treating diseases and disorders through RNAi.Type: GrantFiled: March 19, 2020Date of Patent: April 26, 2022Assignee: Northwestern UniversityInventors: Marcus E. Peter, Andrea E. Murmann
-
Publication number: 20210147853Abstract: Disclosed are compositions and methods related to RNA interference (RNAi) and the use of RNAi active sequence for treating diseases and disorders. Particular disclosed are toxic RNAi active sequences such as siRNA and shRNA for killing cancer cells. The disclosed toxic RNAi active sequences typically include trinucleotide repeats and preferentially target the expression of multiple essential genes for cell survival and/or growth.Type: ApplicationFiled: January 27, 2021Publication date: May 20, 2021Inventors: Marcus E. Peter, Andrea E. Murmann
-
Patent number: 10934547Abstract: Disclosed are compositions and methods related to RNA interference (RNAi) and the use of RNAi active sequence for treating diseases and disorders. Particular disclosed are toxic RNAi active sequences such as siRNA and shRNA for killing cancer cells. The disclosed toxic RNAi active sequences typically include trinucleotide repeats and preferentially target the expression of multiple essential genes for cell survival and/or growth.Type: GrantFiled: February 20, 2018Date of Patent: March 2, 2021Assignee: Northwestern UniversityInventors: Marcus E. Peter, Andrea E. Murmann
-
Publication number: 20200299694Abstract: Disclosed are components and methods for producing toxic RNAs and/or extracellular vesicles comprising the toxic RNAs in cells that are resistant to the toxic RNAs, which toxic RNAs may include toxic shRNA/siRNA and/or toxic pre-miRNA/miRNA. The disclosed components may include engineered cells that can be utilized to express the toxic RNAs, in which the engineered cells do not express one or more genes that are required for processing the toxic RNAs for RNA interference (RNAi) and/or one or more genes that are required for executing RNAi. The toxic RNAs and/or extracellular vesicles comprising the toxic RNAs may be utilized in methods for treating diseases and disorders through RNAi.Type: ApplicationFiled: March 19, 2020Publication date: September 24, 2020Applicant: Northwestern UniversityInventors: Marcus E. Peter, Andrea E. Murmann
-
Publication number: 20200299697Abstract: Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.” The disclosed toxic RNAi active seed sequences may be referred to as “dual activity super toxic RNAi active dsRNAs” that include a toxic first strand and a toxic second strand that is complementary to the toxic first strand. As such, the disclosed dsRNAs may be expressed as shRNAs which are processed for RNA interference (RNAi) and either of the toxic first strand and the toxic second strand can function as a guide strand to initiate RNAi.Type: ApplicationFiled: March 19, 2020Publication date: September 24, 2020Applicant: Northwestern UniversityInventors: Marcus E. Peter, Andrea E. Murmann
-
Publication number: 20180320187Abstract: Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). The disclosed polynucleotides, compositions, and methods may be utilized for treating diseases and disorders through RNAi. Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.Type: ApplicationFiled: February 20, 2018Publication date: November 8, 2018Applicant: Northwestern UniversityInventors: Marcus E. Peter, William E. Putzbach, Andrea E. Murmann, Monal Patel, Quan Gao
-
Publication number: 20180251762Abstract: Disclosed are compositions and methods related to RNA interference (RNAi) and the use of RNAi active sequence for treating diseases and disorders. Particular disclosed are toxic RNAi active sequences such as siRNA and shRNA for killing cancer cells. The disclosed toxic RNAi active sequences typically include trinucleotide repeats and preferentially target the expression of multiple essential genes for cell survival and/or growth.Type: ApplicationFiled: February 20, 2018Publication date: September 6, 2018Applicant: Northwestern UniversityInventors: Marcus E. Peter, Andrea E. Murmann